| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55c7033e5692e9bf2cfa3a5da5a578bc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate |
2013-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_800cb3408bbf9064f13b273dcfa0994a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ca9e5e783e29992a63949327f49bf97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cd30e5bfa8651d97923e33a478b9151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_200e4552b1c5ee1220171a182159db40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1545db8fe5f6f903e094c707e5aef170 |
| publicationDate |
2015-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015330993-A1 |
| titleOfInvention |
Diagnostic, prognostic, therapeutic and screening protocols |
| abstract |
The specification describes an antibody capture process comprising (i) obtaining a biological sample comprising antibodies, (ii) contacting the biological sample with recombinant pIgR or a dIgA-binding variant, wherein the pIgR or variant binds dIgA and forms a pIgR-dIgA complex. The process may further comprise (iii) directly or indirectly assessing the level of the pIgR-dIgA complex or the level of a complex between pIgR-dIgA and an antigen of interest. There is also an antibody capture process for determining gut wall integrity in a test subject, wherein the level or ratio of SIgA to dIgA is compared to a corresponding level or ratio from a control subject. The specification provides kits embodying the process and recombinant pIgR when used for, or for use, in capturing or detecting dIgA and/or IgM. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021026000-A1 |
| priorityDate |
2012-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |